While various studies evaluated tolerability, safety of DPP-4 inhibitors in patients with impaired kidney function and type 2 diabetes mellitus [20-23], information about the outcomes of clinical trials pertaining to primary kidney disease is currently unavailable [24]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.